



The Innovative Medicines Initiative

Hugh Lavery
15th June 2017, HESI ANNUAL MEETING, Dublin


IMI – Europe's partnership for health

IMI1: 2008-2017

€2 bn budget
59 projects

IMI2: 2014-2024

€3.3 bn budget
More ambitious
More open
Greater scope



Goals of IMI 2 programme


- **Improve the drug development process** by creating tools to assess the efficacy, safety and quality of medicines
- **Increase the success rate of clinical trials** of new medicines & vaccines
- **Speed up the earlier stages** of drug development
- **Develop new treatments** for areas of **unmet need**
- **Develop new biological markers** to **diagnose** diseases and **assess** treatments

IMI – key concepts

- Non-competitive collaborative research
- Competitive Calls for proposals
- Open collaboration in public-private consortia
 - Data sharing
 - Dissemination of results...
- Industry contribution is in kind



An international, cross-sector community



Over 9 000 researchers working for:


- open collaboration
- improved R&D productivity
- innovative approaches to unmet medical needs

IMI1 budget distribution per disease area



Budget distribution per disease area

Updated January 2017




IMI2 budget distribution per disease area



Distribution of funding per scientific area

Updated February 2017



ABIRISK - Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk www.abirisk.eu

BIOVACSAFE - Biomarkers for Enhanced Vaccine Immunosafety www.biovacsafe.eu

SAFE-T - Safer and Faster Evidence-based Translation www.imi-safe-t.eu

MARCAR - Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis www.imi-marcar.eu/

MIP-DILI - Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury www.mip-dili.eu

eTOX - Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities www.e-tox.net

TransQST - Translational quantitative systems toxicology to improve the understanding of the safety of medicines transqst.org

iPIE - Intelligent Assessment of Pharmaceuticals in the Environment www.i-pie.org

EU2P - European programme in Pharmacovigilance and Pharmacoepidemiology
www.eu2p.org

SafeSciMet - European Modular Education and Training Programme in Safety Sciences
for Medicines www.safescimet.eu

WEB RADR - Recognising Adverse Drug Reactions web-radr.eu/

PREFER - Patient Preferences in benefit risk assessments during the drug life cycle imi-prefer.eu

PROTECT -Pharmacoepidemiological research on outcomes of therapeutics by a
European consortium www.imi-protect.eu



Stay in touch

- Visit our website
www.imi.europa.eu
- Sign up to our newsletter
bit.ly/IMInewsletter
- Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group
bit.ly/LinkedInIMI
- E-mail us
infodesk@imi.europa.eu



The image shows a composite of the IMI website and its Twitter profile. The website header includes the IMI logo, navigation links (Contact, Newsletter, Links), and a search bar. The main content area features a navigation menu with links to Home, About IMI, Ongoing projects, Calls for proposals, News, Events & Media, and Reference documents. Below the menu are four buttons: PARTNER SEARCH, EDUCATION & TRAINING, SMALL & MEDIUM-SIZED ENTERPRISES, and INTELLECTUAL PROPERTY. A featured article titled 'IMI LAUNCHES EBOLA+ PROGRAMME' is displayed, along with a 'NEWSFLASH' section containing three news items from 2014. A 'NEWSLETTER' section offers a 'Read & subscribe' link, and an 'AGENDA' section lists upcoming events. The Twitter profile below shows the IMI bio, location (Brussels), website, and join date (June 2010). It also displays three tweets from @IMI_JU regarding Ebola-related webinars and diagnostic tests.



Thank you

Hugh Lavery • Head of Scientific Operations

Hugh.Lavery@imi.europa.eu